Abstract: Method of selecting treatment for a subject diagnosed with cancer comprises contacting antibody that binds specifically to thymidine kinase 1 (TK1) protein with a first body fluid sample before completing cancer treatment; determining a first amount of antibody binding to TK1 protein in the first sample; correlating the first amount to a first concentration of TK1 protein using a standard curve correlating an amount of antibody binding to recombinant human TK1 (rhTK1) and a concentration of rhTK1; contacting the antibody with a second body fluid sample within one to six months after the cancer treatment; determining a second amount of antibody binding to TK1 protein in the second sample; correlating the second amount to a second concentration using the curve; identifying the patient as having a high risk of future cancer relapse if the second concentration is ? the first concentration; and selecting an adjuvant treatment based on the identification.
Type:
Grant
Filed:
December 30, 2019
Date of Patent:
April 16, 2024
Assignee:
AROCELL AB
Inventors:
Sven Skog, Staffan Eriksson, Bernard Tribukait, Qimin He
Abstract: Method of determining a likelihood of cancer relapse in a subject who has completed cancer tumor surgery, radiotherapy treatment and/or chemotherapy treatment comprises contacting an antibody that binds specifically to a serum form of thymidine kinase 1 (STK1) protein with a blood serum sample one to six months after completing the surgery and/or treatment, and before any cancer relapse has been detected; determining an amount of antibody binding to STK1 protein in the sample; correlating the amount of antibody binding to STK1 protein to a concentration of STK1 protein in the sample; and based on the concentration of STK1 protein in the sample, generating decision support information representative of a likelihood of cancer relapse in the subject one to ten years after completion of the surgery and/or treatment, the decision support information comprising a likelihood value defining one of a high or low likelihood of cancer relapse.
Type:
Grant
Filed:
November 21, 2016
Date of Patent:
February 4, 2020
Assignee:
AROCELL AB
Inventors:
Sven Skog, Staffan Eriksson, Bernard Tribukait, Qimin He
Abstract: Monoclonal antibodies and fragments thereof are capable of binding to a serum form of human TK1. Kits and methods involve the use of such monoclonal antibodies or fragments.
Abstract: The embodiments relate to monoclonal antibodies or fragments capable of binding to a serum form of human TK1 and to kits and methods involving the use of such monoclonal antibodies or fragments.
Abstract: A method of predicting the likelihood of cancer relapse in a patient undergoing treatment for cancer is provided. The binding response level of an immunoreactive material (IM) comprising thymidine kinase 1 (TK1) protein is determined in a body fluid sample of a patient and the likelihood of relapse of the cancer disease is predicted based on this determined IM binding response level. Those patients that run a risk of cancer progress and relapse 1-15 years after the cancer treatment may be identified directly by the IM binding response level within a few months following initiation of the treatment.
Type:
Application
Filed:
November 27, 2009
Publication date:
December 9, 2010
Applicant:
AROCELL AB
Inventors:
Sven SKOG, Staffan ERIKSSON, Bernhard TRIBUKAIT, Qimin HE